Oncorus to Participate in Upcoming Investor Conferences
November 23 2022 - 8:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced that President and Chief Executive
Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in
two upcoming investor conferences:
- Evercore ISI 5th
Annual HealthCONx Conference: Virtual
fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.
- Piper Sandler 34th Annual Healthcare
Conference: Fireside chat on Thursday, December 1, 2022 at
12:30 p.m. ET in New York, NY.
A webcast of each event can be accessed by visiting the
Investors & Media section of Oncorus’ website
at https://investors.oncorus.com/. A replay of the webcast
will be archived on Oncorus’ website for 90 days following the
event.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to stimulate the immune
system and transform outcomes for cancer patients. We are advancing
a portfolio of intratumorally (iTu) and intravenously (IV)
administered viral immunotherapies for multiple indications with
significant unmet need based on our Herpes Simplex Virus (HSV) and
self-amplifying viral RNA/LNP Platforms.
Designed as a next-generation viral immunotherapy, our HSV
Platform improves upon key characteristics of this therapeutic
class to enhance systemic activity with immune stimulating
payloads. Our lead HSV program, ONCR-177, currently in the clinic,
is designed to be directly administered into a tumor, resulting in
high local concentrations of therapeutic agent and its five encoded
transgenes, as well as low systemic exposure to the therapy, which
could limit systemic toxicities. Our pioneering self-amplifying
vRNA/LNP Platform, highlighted by our product candidates ONCR-021
and ONCR-788, involves a highly innovative, novel combination of
RNA and LNP-based modalities designed to realize the potential of
RNA medicines for cancer.
Please visit www.oncorus.com to learn more. Investor
Contact:Stern Investor Relations Julie
SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024